

Brandes Investment Partners
U.S. Small Cap Value Equity Strategy Notes
Third Quarter 2025 (1 July – 30 September 2025)

The Brandes U.S. Small Cap Value Equity Strategy returned 11.37% (gross of fees), underperforming its benchmark, the Russell 2000 Index, which rose 12.39%, and the Russell 2000 Value Index, which gained 12.60%.

Positive Contributors

Leading contributors included holdings in the health care sector, led by Elanco Animal Health, Phibro Animal Health, service provider Premier, and Avadel Pharmaceuticals. Each company announced strong earnings growth with Elanco benefiting from product momentum in its pet health and farm animal segments. Avadel saw strong sales of its extended-release sleep medication Lumryz. And Premier captured sequential improvement in supply chain services. With their share prices appreciating to our estimates of their respective intrinsic value, we entirely divested Phibro Animal Health and Premier.

Other solid performers included Park Aerospace, Hanesbrands, and energy equipment and services company Innovex International. In August, Gildan Activewear announced it had bought Hanesbrands for \$2.2 billion, with the deal expected to close in late 2025 or early 2026. The acquisition aims to merge the manufacturing strength of Gildan with the retail and brand strength of Hanesbrands.

On a relative basis, our underweight to financials also enhanced performance.

Performance Detractors

Detractors were in the industrials sector, namely machinery companies Kennametal and Hurco Companies, commercial services UniFirst Corporation, as well as construction and engineering business Orion Group. Despite announcing solid earnings, Orion and UniFirst declined on cautious investor sentiment, while the results for Kennametal and Hurco Companies were more mixed. We took advantage of the share-price weakness for Kennametal and UniFirst to add to our positions, while maintaining our allocations to Orion Group and Hurco.

Other detractors included Edgewell Personal Care and leisure products company American Outdoor Brands.

Select Activity in the Quarter

We bought Prestige Consumer Healthcare, information technology (IT) services company Globant, packaging business Sonoco Products Company, and safety, identification and compliance solution company Brady Corporation.

Prestige Consumer Healthcare is an over-the-counter pharmaceutical manufacturer that operates primarily in North America. The company is a brand builder, focused on acquiring underperforming brands and expanding market share through advertising, marketing expertise and product innovation. Its notable brands include BC/Goody's, Monistat, Chloraseptic, Clear Eyes, Compound W, Dramamine and Summer's Eve. Prestige has 17 brands: 12 have market share leadership, while the rest are between second and fourth in their individual markets.

Recent share-price weakness for Prestige created an opportunity to invest in a company we know very well, having owned it for years previously, as recently as earlier this year. Prestige is well positioned as demand for its products is fairly defensive even in tougher economic times because its products are purchased on an "as-needed basis," often annually or biannually. Private label competition is insignificant. The markets are niche, given consumers' tendency to buy branded products for infrequent use, known efficacy, and trust. Topline growth is not high but stable. The key is capital deployment, with Prestige ranking (in order of priority): investing in strategic brands to ensure long-term, organic success, mergers and acquisition, and share repurchases. We take comfort in its track record of prior purchases and the company's stated discipline of being opportunistic and focused on returns.

Globant is a multinational IT services company specialising in high-value digital engineering services, including customer experience, artificial intelligence (AI), cloud, and development operations. Unlike many larger IT services firms that maintain broad exposure to slower-growing segments, Globant operates as a digital pure play, generating nearly all its revenue from advanced, high-margin services. The company's business model is mostly project-based, with limited recurring revenue.

Founded in 2003 and publicly listed since 2014, Globant has delivered organic growth exceeding 20% annually post-IPO. Its client base is geographically diverse; the U.S., Latin America, and Europe serve as its main markets, while Asia and the Middle East represent growing segments. Through its “Studio” model, Globant is known for blending design and technology to produce user-centric digital experiences. Notable clients include Disney, Google, LinkedIn, Electronic Arts, Formula 1, and Coca-Cola.

Operating within the highly competitive and fragmented \$1.5 trillion global IT services industry, Globant benefited from a pandemic-era surge in digital transformation spending. However, the company has recently faced a cyclical slowdown as enterprises focus on cost efficiency and delay discretionary technology investments. Additionally, the rise of generative AI introduces long-term uncertainty, with the potential to automate commoditised tasks and disrupt traditional outsourcing models. These headwinds have contributed to a sharp decline in Globant’s share price, which was down over 70% year-to-date in 2025.

We believe that the cyclical and the AI-related risks have been more than accounted for in Globant’s current market valuation. We like the fact that the company has a healthy balance sheet and strong relationships with its clients. In our view, Globant is well positioned to benefit as IT budgets normalise, and clients move from AI pilots to scaled adoption. It also has the potential to expand its scope of work to more complex, higher-value projects in areas such as product design, data integration, and business process reengineering. At its current valuations, Globant represents an appealing value opportunity to us.

Other portfolio activity included the previously noted sales of Premier and Phibro Animal Health, as well as of regional jet manufacturer Embraer.

Year-to-Date Briefing

The Brandes U.S. Small Cap Equity Strategy rose 17.45%, outperforming its benchmark, the Russell 2000 Index, which delivered 10.39% in the nine months ended 30 September 2025, and the Russell 2000 Value Index, which increased 9.04%.

Stock selection across multiple sectors drove our outperformance relative to the benchmark. Leading contributors included select holdings in health care and industrials, specifically Embraer, Park Aerospace, machinery company Graham Corporation, Elanco Animal Health, and Premier. The strategy also benefited from solid returns delivered by Arlo Technologies and Innovex International.

Detractors were mainly in consumer staples and consumer discretionary sectors, namely Edgewell Personal Care and American Outdoor Brands. Kennametal, household durables business Dorel Industries, and professional services company Resources Connection also declined.

Current Positioning

Allocation to companies in the industrials sector continues to be the largest weighting and relative overweight from a sector standpoint. The portfolio also maintains key weights in health care and consumer discretionary. The strategy’s most notable underweights are in financials, information technology, and real estate. Compared to the Russell 2000 Value Index, we have significantly less exposure to financials and real estate.

In our opinion, the differences between the Brandes U.S. Small Cap Value Equity Strategy and the broader U.S. small-cap market continue to make it an attractive complement to other small-cap offerings. Our strategy exhibits lower valuations than the Russell 2000 Index, while offering exposure to companies that we believe have strong balance sheets, compelling growth prospects, and a history of durable free-cash-flow generation.

We are optimistic about the potential of value stocks in general and believe the Brandes U.S. Small Cap Value Equity Strategy remains well positioned from a long-term risk/reward perspective.

For term definitions, please refer to <https://www.brandes.com/emea/termdefinitions>.

For index definitions, please refer to <https://www.brandes.com/emea/benchmark-definitions>.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes Investment Partners® exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. International and emerging markets investing is subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will

remain in an account's portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any; and (iii) market exigencies at the time of investment. Unlike bonds issued or guaranteed by the U.S. government or its agencies, stocks and other bonds are not backed by the full faith and credit of the United States. Stock and bond prices will experience market fluctuations. Please note that the value of government securities and bonds in general have an inverse relationship to interest rates. Bonds carry the risk of default, or the risk that an issuer will be unable to make income or principal payment. There is no assurance that private guarantors or insurers will meet their obligations. The credit quality of the investments in the portfolio is not a guarantee of the safety or stability of the portfolio. Investments in Asset Backed and Mortgage Backed Securities include additional risks that investors should be aware of such as credit risk, prepayment risk, possible illiquidity and default, as well as increased susceptibility to adverse economic developments. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot guarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a guarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

Ireland/Europe: FOR PROFESSIONAL INVESTOR USE ONLY. Issued by Brandes Investment Partners (Europe) Limited (Brandes Europe), Alexandra House, The Sweepstakes, Ballsbridge, Dublin, D04 C7H2, Ireland. Registered in Ireland Number 510203. Authorised and regulated by the Central Bank of Ireland. This report is being provided for information purposes only, no representation or warranty is made, whether express or implied as to the accuracy or completeness of the information provided. To the fullest extent permitted by law Brandes Europe shall not be liable for any loss or damage suffered by any person as a result of the receipt of this report. Recipients of this report should obtain their own professional advice. The distribution of this report may be restricted by law. No action has been or will be taken by Brandes Europe to permit the possession or distribution of this report in any jurisdiction where action for that purpose may be required. Accordingly, this report may not be used in any jurisdiction except under circumstances that will result in compliance with any applicable laws and regulations. Persons to whom this report is communicated should inform themselves about and observe any such restrictions. This information is being issued only to, and/or is directed only at (i) persons who have professional experience in matters relating to investments or (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or to whom it may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This report is a confidential communication to, and solely for the use of, the persons to whom it is distributed to by Brandes Europe.